News
FDA advises Lipocine that it is working towards action on the NDA for Tlando to treat hypogonadism on or about 30 November 2020.
Lipocine Inc. announced that the FDA has informed the Company that it is working towards taking action on the Tlando New Drug Application on or about the week of November 30, 2020.
However, the Company cannot assure that the FDA will act in that time frame. Tlando is the Company's oral testosterone product candidate for testosterone replacement therapy in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism.
Condition: Testosterone Deficiency
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins